SLU-PP-332
Also known as: SLU-PP-332
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRs) studied as an exercise mimetic that increases fat oxidation and endurance in animal models. It is a research chemical, not a peptide.
Last updated
Mechanism of Action
SLU-PP-332 is a small-molecule agonist of the estrogen-related receptors ERRalpha, ERRbeta, and ERRgamma, orphan nuclear receptors that govern mitochondrial biogenesis and oxidative metabolism. By activating ERRs, the compound up-regulates genes in the fatty-acid oxidation and oxidative phosphorylation programs, shifting cellular fuel use toward fat and increasing mitochondrial capacity in skeletal muscle. In rodent studies this drives a phenotype resembling endurance exercise, with greater running capacity, increased energy expenditure, and resistance to diet-induced obesity, hence the description as an exercise mimetic.
- Half-life
- Short in rodents (on the order of hours); human pharmacokinetics not established
- Administration Routes
- subcutaneous, oral
- Research Status
- Preclinical
Reported Benefits
- Increases mitochondrial biogenesis via ERR activation
- Enhances fatty-acid oxidation and energy expenditure in animal models
- Improved running endurance in rodent studies
- Reduced diet-induced weight gain in preclinical work
- Investigated as an exercise-mimetic for metabolic disease
Potential Side Effects
- Human safety profile not established
- Possible effects on heart rate and cardiac metabolism (theoretical)
- Unknown long-term metabolic and hormonal effects
- Injection-site reactions if administered parenterally
Common Dosing
Research-use only and not medical advice; no validated human dosing exists. Rodent studies have used weight-based dosing administered by injection, and these do not translate directly to humans.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Pregnancy and breastfeeding
- Use in humans outside controlled research
- Known cardiac arrhythmia given unknown cardiometabolic effects
AICAR
AICAR (Acadesine) is an AMPK-activating compound studied as an exercise-mimetic for endurance and metabolic effects in animals. Note: AICAR is a small-molecule nucleoside (an AMPK activator), not a peptide, but is commonly sold alongside research peptides.
MOTS-c
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA region that acts as a regulator of metabolism. It is studied for improving insulin sensitivity, metabolic flexibility, and exercise capacity.
5-Amino-1MQ
5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, studied in animal models for its potential to reduce fat storage and support metabolic health.
- View
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
2023
- View
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
2024
- View
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
2024
- View
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney
2023
- View
Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.
2025